Navigation Links
Study finds plasmin -- delivered through a bubble -- more effective than tPA in busting clots
Date:5/15/2013

troke is intravenous delivery of U.S. Food and Drug Administration-approved rt-PA within three hours of stroke onset. Ischemic stroke is the most common type of stroke, accounting for about 87 percent of all stroke cases.

But Shaw says there is a "critical need" for a safer and more effective thrombolytic, as rt-PA carries a risk of bleeding. Intracranial hemorrhage currently occurs in 6 percent of patients receiving rt-PA therapy.

"Previous in vivo studies have demonstrated better safety of plasmin as compared with rt-PA," he says. "Currently, intra-arterial plasmin is undergoing clinical trials. Our next step is to work on targeting the liposome by putting antibodies on its surface that will stick it to the clot. We also want to improve the efficiency of encapsulating the plasmin in the liposome. Right now, about 15 percent of the plasmin gets into the liposomewe're aiming for 50 percent."


'/>"/>

Contact: Katy Cosse
kcosse@gmail.com
513-309-3180
University of Cincinnati Academic Health Center
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Study: FOLFIRINOX Followed by Chemoradiation Shows Substantial Activity in Locally Advanced Pancreatic Cancer
2. Preclinical study shows heroin vaccine blocks relapse
3. New Study on Cordyceps Sinensis (Hirsutella Sinensis) Shows Anti-Inflammatory Properties
4. New Study: Valtrex (Valacyclovir) Side Effects Target the Brain; polyDNA Suggests a Natural Herpes Remedy
5. Wysebridge Patent Bar Review Launches America Invents Act (AIA) Study Suite
6. Breath study brings roadside drug testing closer
7. Japan Bioinformatics Announces Release of a Case Study on Detecting SNPs and Short INDELs
8. Research Foundations Collaborate To Fund Phase 1 Study Of Cancer Drug In Alzheimers Disease Patients
9. Ceregene Reports Data From Parkinsons Disease Phase 2b Study
10. Study Says Kidney Bean Leaves Work Against Bed Bugs, My Cleaning Products Compares Its With a Non-Pesticide Bed Bug Spray
11. NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy ... that it has signed a letter of intent ... has developed and patented a nanotechnology-based development platform ... products that enable rapid on-site collection and testing ... and health issues in an immediate, non-invasive and ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Fertility Associates ... Donor Egg Bank USA , a network of more ... Through this partnership, patients have fast access to a ... vitro fertilization, IVF . Fertility Associates of Memphis is ... this fertility treatment option. , Dr. William Kutteh ...
(Date:12/19/2014)... Calif. , Dec. 19, 2014  Roche (SIX: ... of Bina Technologies, Inc. (Bina), a privately held ... , USA. Bina provides a big data ... generation sequencing (NGS) data. Bina,s proprietary on-market Genomic ... and academic researchers to perform fast and scalable ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3
... Boehringer Ingelheim today,announced that the company ... as the,world,s most respected biopharmaceutical employer. Science,s ... polls employees in the biotechnology,biopharmaceutical, pharmaceutical, and ... asked to rate companies based on 23 ...
... featured in oral presentation ... TSX Exchange Symbol: ... is pleased to announce that tomorrow it is making,an oral ... at the International Atherosclerosis Society (IAS),Workshop on HDL. The presentation ...
... New sol-gel inks developed by researchers at the University ... three-dimensional structures of metal oxides with nanoscale features. , ... nanoscale opens a new avenue to functional devices. Potential ... The researchers describe the new inks in a paper ...
Cached Biology Technology:Boehringer Ingelheim Receives Top Honor as World's Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 2Boehringer Ingelheim Receives Top Honor as World's Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 3Resverlogix is Presenting at IAS HDL Workshop 2Sol-gel inks produce complex shapes with nanoscale features 2
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a leader ... million in Series A1 funding led by UK-based Eurovestech. ... participated in the investment round. "We are ... community adopts next-generation sequencing and seeks new approaches for ... Reid Robison , MD MBA, and CEO of Tute ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... Orleans, LA Research led by Wayne L. Backes, PhD, ... Health Sciences Center New Orleans School of Medicine, has found ... present in an individual, but also how they interact, and ... safely eliminated from the body or is converted into a ...
... Pa. , March 17 Orbel,s ... design your own PCB shield. Visit the BLS section ... from a wide variety of surface mount or ... The easy-to-use application lets you enter shield dimensions, ...
... A new study involving scientists from 13 different ... protection offers one of the most effective, practical, ... study, "Indigenous Lands, Protected Areas, and Slowing Climate ... a peer-reviewed scientific journal, and makes specific recommendations ...
Cached Biology News:LSUHSC research increases understanding of drug metabolism 2Orbel Introduces the Board Shielding Wizard 2Study highlights forest protected areas as a critical strategy for slowing climate change 2
... through 63 ligand binding ... a broad therapeutic range. ... many non human tissue ... assays. Used to ...
...
... Sequencer 20 System revolutionizes DNA sequencing, delivering ... The Genome Sequencer 20 System includes: ... and consumables for library construction, amplification, and ... de novo assembly The ...
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
Biology Products: